Cost‐utility of once‐weekly insulin icodec versus once‐daily basal insulins for type 2 diabetes in China
Authors' conclusion
Once-weekly icodec represents a cost-effective and clinically beneficial alternative to once-daily basal insulin analogues for Chinese adults with type 2 diabetes within the current reimbursement framework.
Study context
- Population
- Chinese adults with T2D within reimbursement context; model based on ONWARDS 5 data
- Comparison
- Once-weekly insulin icodec vs once-daily basal insulin analogues
- Outcome
- Cost-utility
- Follow-up
- 40-year time horizon
Methodological detailslong-term, Chinese healthcare system perspective, 40-year time horizon, 5% annual discount rate, sensitivity and scenario analyses
- Long-term
- Chinese healthcare system perspective
- 40-year time horizon
- 5% annual discount rate
- Sensitivity and scenario analyses
Main finding
As reported in the abstract
- Additional quality-adjusted life-years (QALYs) with icodec
- 0.261
- Increased life expectancy with icodec
- 0.031 years
- Reduction in total costs with icodec (700 U)
- $2544.93
- Reduction in total costs with icodec (1050 U)
- $2,916.92
- Probabilistic sensitivity analysis: cost-effectiveness at below 0.4 times China's GDP per capita
- 100%
Further findings
| Outcome | RR |
|---|---|
| Cardiovascular mortality | 0.97 |
Cardiovascular mortality
- Lower cumulative incidence of microvascular and macrovascular complications with icodec
Original publication
Cost‐utility of once‐weekly insulin icodec versus once‐daily basal insulins for type 2 diabetes in China. Diabetes Obes Metab. Published 18 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →